Customize your JAMA Network experience by selecting one or more topics from the list below.
In the From the Food and Drug Administration column published in the
February 4, 1998, issue of THE JOURNAL (1998;279:346), there was incorrect
wording under the heading "Two New Warnings Added to Labeling for Mibefradil."
Mibrefadil is not contraindicated for patients concurrently receiving fluvastatin.
The 2 drugs for which a new warning states that concurrent use with Mibefradil
is contraindicated are lovastatin and simvastatin.
Incorrect Wording. JAMA. 1998;279(12):913. doi:10.1001/jama.279.12.913
Monkeypox Resource Center